Kanabo Group signs new EU GMP CBD manufacturing agreement

LONDON: Kanabo Group Plc (LON: KNB) has signed an agreement with Pure Origin Limited and its affiliates to utilise their significant expertise in best practices for EU GMP manufacturing.

Good Manufacturing Practices (GMPs) are systems created and authorised by the government to regulate production, verification and validation of drugs, food and/or medical devices, ensuring that finished products are effective and safe for market distribution.

Under the agreement Pure Origin and its affiliates will manufacture, package and supply Kanabo’s CBD wellness product line from their EU GMP manufacturing facility in Wales. The partnership for Kanabo’s CBD wellness product line with EU GMP manufacturing, ensures that consumers will continue to receive the highest quality of consistent, traceable, safe, and compliant products.

As stated in the agreement, Pure Origin and Kanabo will establish a dedicated production line for the VapePod’s CBD Wellness formulas that will use Kanabo’s equipment, production protocols and IP. Kanabo will supply raw materials to Pure Origin for the preparation of CBD formulations and final packaging. The current production line will have an initial capacity of 44,000 units a month with the ability to further increase production when necessary.

This new agreement marks the end of the period of pilot sales and is the prelude to a full product launch internationally. The pilot period lasted 3 months from admission to the London Stock Exchange and has provided a number of important performance measures in relation to the sale of Kanabo’s retail CBD products in the UK. The outcome of the pilot has formed the second phase of Kanabo’s strategy to increase revenue from the sale of CBD products, and Kanabo’s future long-term strategy involves continued research and development activities to develop a range of Unlicensed Medical Cannabis Oils, which will be sold as unlicensed medical products.

Kanabo Group is a medical cannabis R&D Company that focuses on the distribution of cannabis-derived products for medical patients, and non-THC products for CBD consumers.

Kanabo Group PLC (LON: KNB)

Share price

18.09 GBX 0.00 (0.00%)

19 May, 6:06 pm GMT+1 · Disclaimer

www.kanabogroup.com

Leave a Reply

Your email address will not be published. Required fields are marked *